By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



300 George Street

New Haven  Connecticut  06511  U.S.A.
Phone: 203-848-1234 Fax: 203-848-6007



Company News
ZIOPHARM Abandons $50 Million Stock Offering After Clinical Trial Deaths 7/15/2016 6:17:01 AM
ZIOPHARM, Inc. Announces First Patient Enrolled In Phase I Study Of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy For Advanced Lymphoid Malignancies 2/9/2016 8:00:38 AM
ZIOPHARM, Inc. Appoints Scott Tarriff To Its Board Of Directors 9/28/2015 10:53:26 AM
Intrexon (XON) Announces Distribution Ratio For Distribution Of ZIOPHARM Shares 6/5/2015 6:39:35 AM
ZIOPHARM, Inc. Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients With Locally Advanced or Metastatic Breast Cancer 4/27/2015 7:34:00 AM
CAR-T Cell Companies Juno Therapeutics (JUNO), Kite Pharma (KITE), and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG (NVS) Trial News 4/21/2015 6:39:03 AM
ZIOPHARM, Inc. Reports Second-Quarter 2014 Financial Results And Reviews Recent Activities 8/8/2014 10:47:32 AM
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014 3:18:52 PM
ZIOPHARM, Inc. Announces FDA Acceptance of IND for Oral Palifosfamide 2/6/2012 9:52:18 AM
ZIOPHARM, Inc. Granted European Patent Allowance for Palifosfamide 12/7/2011 6:23:44 AM